Nearly All Nursing Homes Fail Federal Rules on Anti-Psychotics
A year ago, the OIG, which is a branch of the U.S. Department of Health and Human Services, published a report saying that about half of anti-psychotic medications given to Medicare beneficiaries in nursing homes were not for medically accepted indications, and one in five were not given in accordance with federal safeguards to protect residents from unnecessary use.
The latest report takes the investigation one step further by looking at whether all four requirements in the process of determining appropriate use of those anti-psychotics in nursing homes were met.
The OIG recommends that the Centers for Medicare & Medicaid Services should do more to improve the process, specifically by modifying the survey "to target a small subsample of residents receiving anti-psychotic drugs focusing on the quality of care for these particularly vulnerable residents."
Also, CMS could require that nursing facilities document any efforts “to include the participation of residents, their families, or their legal representatives" in developing care plans.
- As Medicare Advantage Cuts Loom, Disagreement Over Program's Stability
- Medicare Advantage Carriers See 'No Choice' But to Accept Cuts
- 3 Management Lessons from a Supermarket Debacle
- Physicians to Appeal 'Docs v. Glocks' Ruling in FL
- Centralizing the Revenue Cycle Protects the Bottom Line
- CA Fines 8 Hospitals for Medical Errors
- Revenue Cycles Get a Boost from Simple JPEG Files
- IOM Identifies GME Problems, Calls for Finance Changes
- Employers Weigh Risks, Benefits of Private Exchanges
- Doctors Feel Pressure to Accept Risk-based Reimbursement